Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond

Seminars in Thrombosis and Hemostasis

Volumn 31, Issue 6, 2005, Pages 625-632

  Lian, Eric Chun Yet ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

ADAMTS13; Autoantibodies; Platelet aggregation; Thrombotic thrombocytopenic purpura (TTP); Vascular injury

Indexed keywords

AUTOANTIBODY; BLOOD CLOTTING INHIBITOR; CLOPIDOGREL; IMMUNOGLOBULIN G; TICLOPIDINE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

APOPTOSIS; AUTOIMMUNITY; BLOOD VESSEL INJURY; CELL ACTIVATION; ENZYME ACTIVITY; ENZYME DEFICIENCY; FIBRINOLYSIS; GENE MUTATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; MICROCIRCULATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SHEAR STRESS; THROMBOCYTE AGGREGATION; THROMBOCYTOPOIESIS; THROMBOGENESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; BLOOD COAGULATION; FIBRINOLYSIS; HUMANS; MICROCIRCULATION; PLATELET AGGREGATION; PURPURA, THROMBOTIC THROMBOCYTOPENIC; VON WILLEBRAND FACTOR;

EID: 30344483206     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-925468     Document Type: Review

References (81)

1. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc N Y Pathol Soc 1924;24:21-24
2. Gore I. Disseminated arteriolar and capillary platelet thrombosis; a morphologic study of its histogenesis. Am J Pathol 1950;26(1):155-175
3. Feldman JD, Mardiney MR, Unanue ER, et al. The vascular pathology of thrombotic thrombocytopenic purpura: An immunohistochemical and ultrastructural study. Lab Invest 1966;15:927-946
4. Asada Y, Sumiyoshi A, Hayashi T, et al. Immunohistochemistry of vascular lesions in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res 1985;38:469-479
5. Schulman I, Pierce M, Lukens A, Currimbhoy Z. Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency. Blood 1960;16:943-957
6. Upshaw JD. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med 1978;298:1350-1352
7. Moake JL, Rudy CK, Troll JH. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307:1432-1435
8. Furlan M, Robles R, Solenthaler M, et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997;89:3097-3103
9. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-1584
10. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-1594
11. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenia purpura. Nature 2001;413(6855):488-494
12. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001;98:1662-1666
13. Gerritsen HE, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 2001;98:1654-1661
14. Zheng X, Chung D, Takayama TK, et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001;276:41059-41063
15. Moake JL, Rudy CK, Troll JH, et al. von Willebrand factor abnormalities and endothelial cell perturbation in a patient with acute thrombotic thrombocytopenic purpura. Am J Med Sci 1986;291(1):47-50
16. Mannucci PM, Lombardi R, Lattuada A, et al. Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Blood 1989;74(3):978-988
17. Moake JL, McPherson PD. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. Am J Med 1989; 87(3N):9N-15N
18. Galbusera M, Benigni A, Paris S, et al. Unrecognized pattern of von Willebrand factor abnormalities in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. J Am Soc Nephrol 1999;10(6):1234-1241
19. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98(6):1765-1772
20. Wagner DD. Storage and secretion of von Willebrand factorIn: Ruggeri ZM, Zimmerman TS Coagulation and Bleeding Disorders: The Role of Factor VIII and von Willebrand Factor. New York and Basel: Marcel Dekker; 1989:161-180
21. Wagner DD. The Weibel-Palade body: the storage granule for von Willebrand factor and P-selectin. Thromb Haemost 1993;70:105-110
22. Ruggeri ZM, Dent JA, Saldivar E. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood 1999;94:172-178
23. Berkowitz SD, Dent J, Roberts J, et al. Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin. J Clin Invest 1987;79(2):524-531
24. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Nad Acad Sci USA 1990;87:6306-6310
25. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996;87:4235-4244
26. Furlan M, Robles R, Lammie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996;87:4223-4234
27. Goto S, Ikeda Y, Saldivar E, Ruggeri ZM. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest 1998;101: 479-486
28. Siedlecki CA, Lestini BJ, Kottke-Marchant K, et al. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 1996;88:2939-2950
29. Dong JF, Moake JL, Bernardo A, et al. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem 2003;278(32): 29633-29639
30. Ajzenberg N, Denis CV, Veyradier A, et al. Complete defect in vWF-cleaving protease activity associated with increased shear-induced platelet aggregation in thrombotic micro-angiopathy. Thromb Haemost 2002;87(5):808-811
31. Yagi H, Konno M, Kinoshita S, et al. Plasma of patients with Upshaw-Schulman syndrome, a congenital deficiency of von Willebrand factor-cleaving protease activity, enhances the aggregation of normal platelets under high shear stress. Br J Haematol 2001;115(4):991-997
32. Lopez JA, Dong JF. Cleavage of von Willbrand factor by ADAMTS-13 on enodothelial cells. Semin Hematol 2004; 41:15-23
33. Federici AB, Bader R, Pagani S, et al. Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric size. Br J Haematol 1989; 73(l):93-99
34. Tsai HM. Von Willebrand factor. ADAMTS 13 and thrombotic thrombocytopenic purpura. J Mol Med 2002;80: 639-647
35. Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood 2005;106:11-17
36. Kokame K, Matsumoto M, Soejima K, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 2002;99:11902-11907
37. Zhou W, Inada M, Lee TP, et al. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest 2005;85(6):780-788
38. Matsumoto M, Kokame K, Soejima K, et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood 2004;103: 1305-1310
39. Assink K, Schiphorst R, Allford S, et al. Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency. Kidney Int 2003;63:1995-1999
40. Uchida T, Wada H, Mizutani M, et al. Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura. Blood 2004;104: 2081-2083
41. Veyradier A, Lavergne JM, Ribba AS, et al. Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). J Thromb Haemost 2004;2:424-429
42. Pimanda JE, Maekawa A, Wind T, et al. Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13. Blood 2004;103:627-629
43. Savasan S, Lee SK, Ginsburg D, Tsai HM. ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity. Blood 2003;101:4449-4451
44. Schneppenheim R, Budde U, Oyen F, et al. von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood 2003;101:1845-1850
45. Licht C, Stapenhorst L, Simon T, Budde U, Schneppenheim R, Hoppe B. Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS). Kidney Int 2004;66:955-958
46. Vesely SK, George JN, Lämmle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102:60-68
47. Peyvandi F, Ferrari S, Lavoretano S, Canciani MT, Mannucci PM. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Br J Haematol 2004;127(4):433-439
48. Matsumoto M, Yagi H, Ishizashi H, Wada H, Fujimura Y. The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Semin Hematol 2004; 41(1):68-74
49. Rieger M, Mannucci PM, Hovinga JA, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005;106(4): 1262-1267
50. Soejima K, Matsumoto M, Kokame K, et al. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood 2003;102:3232-3237
51. Klaus C, Plaimauer B, Studt J-D, et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 2004;103:4514-4519
52. Scheiflinger F, Knobl P, Trattner B, et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003;102(9):3241-3243
53. Albert LJ, Inman RD. Mechanisms of Disease: Molecular Mimicry and Autoimmunity. N Engl J Med 1999;341:2068-2074
54. Davidson A, Diamond B. Advances in immunology: autoimmune diseases. N Engl J Med 2001;345:340-350
55. Tsai HM, Rice L, Sarode R, Chow TW, Moake JL. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000;132(10):794-799
56. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000;342(24):1773-1777
57. Schults DR, Arnold PI, Ji W, et al. AntiCD36 autoantibodies in thrombotic thrombocytopenic purpura and other thrombotic disorders: identification of an 85 KD form of CD36 as a target antigen. Br J Haematol 1998;103:849-857
58. Wight JF, Wang H, Horstein A, et al. Characterization of platelet glycoproteins and platelet/endothelial cell antibodies in patients with thrombotic thrombocytopenic purpura. Br J Haematol 1999;107:546-555
59. Galbusera M, Benigni A, Paris S, et al. Unrecognized pattern of von Willebrand factor abnormalities in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. J Am Soc Nephrol 1999;10(6):1234-1241
60. Motto D, Zhang W, Zhu G, et al. Additional environmental and/or genetic factors are required to trigger TTP in ADAMTS13-deficient mice. Blood 2004;104:258
61. Hovinga JAK, Studt J-D, Alberio L, von Lammle B. Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Semin Hematol 2004;41:75-82
62. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and non-idiopathic thrombotic thrombocytopenic purpura. Blood 2004;103:4043-4049
63. Bohm M, Betz C, Miesbach W, et al. The course of ADAMTS13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exachange and vicnrsitine. Br J Haematol 2005;129:644-652
64. Altschule MD. The Kidney: Medical and Surgical Disease. New York: Grume & Stratton; 1953:458
65. Mitra D, Jaffe EA, Weksler B, et al. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood 1997;89:1224-1234
66. Dang CT, Magid MS, Weksler B, et al. Enhanced endothelial cell apoptosis in splenic tissues of patients with thrombotic thrombocytopenic purpura. Blood 1999;93:1264-1270
67. Wu XW, Li ZY, Lian EC. Plasma from a patient with thrombotic thrombocytopenic purpura induces endothelial cell apoptosis and platelet aggregation. Thromb Res 1999; 93(2):79-87
68. Jimennez JJ, Ji W, Mauro LM, et al. Endothelial micro-particles released in thrombotic thrombocytopenic purpura express von Willbrand factor and markers of endothelial activation. Br J Haematol 2003;123:896-902
69. Lian EC-Y, Harkness DR, Byrnes JJ, Wallach H, Nunez R. The presence of a platelet aggregating factors in the plasma of patients with thrombotic thrombocytopenic purpura and its inhibition by normal plasma. Blood 1979;53:333-338
70. Suehiro A, Yoshimoto H, Higasa S, Kakishita E. Platelet aggregating activity of plasma in patients with thrombotic thrombocytopenic purpura evaluated by a particle counting method using light scattering. Int J Hematol 1999;70: 40-46
71. Ahn YS, Jy W, Kolodny L, et al. Activated platelet aggregates in thrombotic thrombocytopenic purpura: decrease with plasma infusions and normalization in remission. Br J Haematol 1996;95:408-415
72. Lian EC-Y, Mu PTK, Siddiqui FA, Chiu AY, Chiu LL. Inhibition of aggregating activity in thrombotic thrombocytopenic purpura plasma by normal adult immunoglobulin G. J Clin Invest 1984;73:548-555
73. Siddiqui FA, Lian ECY. Platelet aggregation protein p37 from a thrombotic purpura. J Clin Invest 1986;76:1330-1337
74. Lian EC-Y. The role of increased platelet aggregation in TTP. Semin Thromb Hemost 1980;6:401-415
75. Chen S-H, Lian EC-Y, Zhang X, Zhan MX. Purification and some properties of platelet aggregating protein (PAP) from the plasma of a patient with thrombotic thrombocytopenic purpura. Natl Med J China 1989;69:382-384
76. Kwaan HC. The pathogenesis of thrombotic thrombocytopenic purpura. Semin Thromb Hemost 1979;5(3):84-98
77. Glas-Greenwalt P, Hall JM, Panke TW, et al. Fibrinolysis in health and disease: abnormal levels of plasminogen activator, plasminogen activator inhibitor, and protein C in thrombotic thrombocytopenic purpura. J Lab Clin Med 1985;108:415-422
78. Lian EC-Y, Nunez RL, Harkness DR. In vivo and in vitro effects of thrombin and plasmin on human Factor VIII (AHF). Am J Hematol 1976;1:481-491
79. Hamilton KK, Fretto LJ, Grierson DS, McKee PA. Effects of plasmin on von Willebrand factor multimers. Degradation in vitro and stimulation of release in vivo. J Clin Invest 1985; 76(1):261-270
80. Kunicki TJ, Montgomery RR, Schullek J. Cleavage of human von Willebrand factor by platelet calcium-activated protease. Blood 1985;65(2):352-356
81. Jelenska M, Kopec M, Sopata I, et al. Fibrinogen does not protect von Willebrand factor against proteolysis by human cathepsin G. Thromb Res 1991;61(4):433-440